Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease

Gut

Volumn 50, Issue 2, 2002, Pages 206-211

  Ten Hove, T ^a   Van Montfrans, C ^a   Peppelenbosch, M P ^a   Van Deventer, S J H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; INFLIXIMAB; PROTEIN BAX; PROTEIN BCL 2;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DRUG EFFECT; HUMAN; HUMAN CELL; LAMINA PROPRIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD3; APOPTOSIS; BIOLOGICAL MARKERS; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL MUCOSA; JURKAT CELLS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0036151047     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.50.2.206     Document Type: Article

References (37)

1. Experimental models of inflammatory bowel disease
2. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease
3. Tumour necrosis factor and inflammatory bowel disease
4. Tumour necrosis factor and Crohn's disease
5. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease
6. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
7. A short-term study of chimeric monoclonal antibody Ca2 to tumor necrosis factor alpha for Crohns-disease
8. Infliximab for the treatment of fistulas in patients with Crohn's disease
9. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-α antibody on markers of coagulation and fibrinolysis in patiens with active Crohn's disease
10. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
11. Anti-TNF therapy decreases production of chemokines in patients with Crohn's disease
12. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
13. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
14. Homeostasis and self-tolerance in the immune system: Turning lymphocytes off
15. T cells from baxalpha transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53 gene product
16. The action of Bax and bcl-2 on T cell selection
17. The proto-oncogene Bcl-2 and its role in regulating apoptosis
18. The Bcl-2 protein family: Arbiters of cell survival
19. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
20. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis
21. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance
22. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique
23. Measurements of antibodies specific for DNA
24. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions
25. CD4 antibody treatment in patients with active Crohn's disease: A phase 1 dose finding study
26. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis
27. A major role for matrix metalloproteinases in T cell injury in the gut
28. Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: Selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression
29. Cytokine-induced survival of activated T cells in vitro and in vivo
30. NF-kappaB regulates Fas/APO-1/CD95- and TCR-mediated apoptosis of T lymphocytes
31. Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking
32. Molecular basis of T cell inactivation by CTLA-4
33. Induction of Fas (Apo-l, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins
34. Caspase-dependent ceramide production in Fas- and HLA class l-mediated peripheral T cell apoptosis
35. Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells
36. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
37. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis